|
Oncogenes and Tumor Suppressors
Citations 321-330 of 795 total displayed.
|
Past content
(since May 2000):
|
Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL
- Belinda Austen, Judith E. Powell, Azra Alvi, Ian Edwards, Laura Hooper, Jane Starczynski, A. Malcolm R. Taylor, Christopher Fegan, Paul Moss, and Tatjana Stankovic
Blood 2005; 106: 3175-3182.
[Abstract]
[Full text]
[PDF]
The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFR and FIP1L1-PDGFR in vitro and in vivo
- Elizabeth H. Stover, Jing Chen, Benjamin H. Lee, Jan Cools, Elizabeth McDowell, Jennifer Adelsperger, Dana Cullen, Allison Coburn, Sandra A. Moore, Rachel Okabe, Doriano Fabbro, Paul W. Manley, James D. Griffin, and D. Gary Gilliland
Blood 2005; 106: 3206-3213.
[Abstract]
[Full text]
[PDF]
Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes
- Fanny Rubio-Moscardo, David Blesa, Cinta Mestre, Reiner Siebert, Theo Balasas, Adalberto Benito, Andreas Rosenwald, Joan Climent, Jose I. Martinez, Markus Schilhabel, E. Lorraine Karran, Stefan Gesk, Manel Esteller, Ronald deLeeuw, Louis M. Staudt, Jose Luis Fernandez-Luna, Daniel Pinkel, Martin J. S. Dyer, and Jose A. Martinez-Climent
Blood 2005; 106: 3214-3222.
[Abstract]
[Full text]
[PDF]
Gefitinib induces myeloid differentiation of acute myeloid leukemia
- Kimberly Stegmaier, Steven M. Corsello, Kenneth N. Ross, Jenny S. Wong, Daniel J. DeAngelo, and Todd R. Golub
Blood 2005; 106: 2841-2848.
[Abstract]
[Full text]
[PDF]
Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia
- Tatsuya Suzuki, Hitoshi Kiyoi, Kazutaka Ozeki, Akihiro Tomita, Satomi Yamaji, Ritsuro Suzuki, Yoshihisa Kodera, Shuichi Miyawaki, Norio Asou, Kazutaka Kuriyama, Fumiharu Yagasaki, Chihiro Shimazaki, Hideki Akiyama, Miki Nishimura, Toshiko Motoji, Katsuji Shinagawa, Akihiro Takeshita, Ryuzo Ueda, Tomohiro Kinoshita, Nobuhiko Emi, and Tomoki Naoe
Blood 2005; 106: 2854-2861.
[Abstract]
[Full text]
[PDF]
The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients
- Philipp S. Goerttler, Cordula Steimle, Edith März, Peter L. Johansson, Björn Andreasson, Martin Griesshammer, Heinz Gisslinger, Hermann Heimpel, and Heike L. Pahl
Blood 2005; 106: 2862-2864.
[Abstract]
[Full text]
[PDF]
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation
- Jason Gotlib, Caroline Berubé, Joseph D. Growney, Ching-Cheng Chen, Tracy I. George, Christopher Williams, Tomohiro Kajiguchi, Jia Ruan, Stan L. Lilleberg, Jeffrey A. Durocher, Jack H. Lichy, Yanfeng Wang, Pamela S. Cohen, Daniel A. Arber, Michael C. Heinrich, Len Neckers, Stephen J. Galli, D. Gary Gilliland, and Steven E. Coutré
Blood 2005; 106: 2865-2870.
[Abstract]
[Full text]
[PDF]
Differential regulation of the p70 S6 kinase pathway by interferon (IFN) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells
- Simrit Parmar, Jessica Smith, Antonella Sassano, Shahab Uddin, Efstratios Katsoulidis, Beata Majchrzak, Suman Kambhampati, Elizabeth A. Eklund, Martin S. Tallman, Eleanor N. Fish, and Leonidas C. Platanias
Blood 2005; 106: 2436-2443.
[Abstract]
[Full text]
[PDF]
Targeting FLT3 in primary MLL-gene–rearranged infant acute lymphoblastic leukemia
- Ronald W. Stam, Monique L. den Boer, Pauline Schneider, Peter Nollau, Martin Horstmann, H. Berna Beverloo, Ella van der Voort, Maria G. Valsecchi, Paola de Lorenzo, Stephen E. Sallan, Scott A. Armstrong, and Rob Pieters
Blood 2005; 106: 2484-2490.
[Abstract]
[Full text]
[PDF]
Cooperating cancer-gene identification through oncogenic-retrovirus–induced insertional mutagenesis
- Yang Du, Sally E. Spence, Nancy A. Jenkins, and Neal G. Copeland
Blood 2005; 106: 2498-2505.
[Abstract]
[Full text]
[PDF]
|
|
